Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review
Publication date: August 2017 Source:Biomedicine & Pharmacotherapy, Volume 92 Author(s): Komal Anjum, Bibi Ibtesam Shagufta, Syed Qamar Abbas, Seema Patel, Ishrat Khan, Sayed Asmat Ali Shah, Najeeb Akhter, Syed Shams ul Hassan Glioblastoma multiforme (GBM) is the deadliest form of heterogeneous brain cancer. It affects an enormous number of patients every year and the survival is approximately 8 to 15 months. GBM has driven by complex signaling pathways and considered as a most challenging to treat. Standard treatment of GBM includes surgery, radiation therapy, chemotherapy and also the combined treatment. This review article described inter and intra- tumor heterogeneity of GMB. In addition, recent chemotherapeutic agents, with their mechanism of action have been defined. FDA-approved drugs also been focused over here and most importantly highlighting some natural and synthetic and novel anti- glioma agents, that are the main focus of researchers nowadays.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Glioma | Neurology | Radiation Therapy